Loading clinical trials...
Loading clinical trials...
A Phase 1 Open-label, Multicenter Study to Evaluate the Effect of Ripretinib on the Pharmacokinetics of a CYP2C8 Probe Substrate (Repaglinide) in Patients with Advanced Gastrointestinal Stromal Tumors (GIST)
Conditions
Interventions
Ripretinib
Repaglinide
Locations
3
United States
Mayo Clinic Florida
Jacksonville, Florida, United States
Sylvester Comprehensive Cancer Center
Miami, Florida, United States
Oregon Health & Science University
Portland, Oregon, United States
Start Date
September 22, 2021
Primary Completion Date
November 16, 2023
Completion Date
July 29, 2024
Last Updated
September 19, 2024
Lead Sponsor
Deciphera Pharmaceuticals, LLC
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions